8-K: Insmed's BRINSUPRI Approved in EU for NCFB Treatment

Insmed's BRINSUPRI receives European Commission approval as the first and only treatment for non-cystic fibrosis bronchiectasis in patients aged 12 and older.

Summary

• The European Commission (EC) has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
• BRINSUPRI is the first and only approved treatment for NCFB in the European Union (EU), representing a first-in-disease, first-in-class DPP1 inhibitor targeting neutrophilic inflammation.
• The approval was based on data from the Phase 3 ASPEN and Phase 2 WILLOW studies, both published in the New England Journal of Medicine.
• In the ASPEN study, patients receiving BRINSUPRI 25 mg experienced a 19.4% reduction in the annual rate of exacerbations compared to placebo.
• BRINSUPRI 25 mg also significantly prolonged the time to first exacerbation, increased the proportion of exacerbation-free patients, and showed statistically significant less decline in lung function (FEV1) at week 52.
• NCFB is a serious, progressive lung disease affecting an estimated 600,000 diagnosed people in the EU, with approximately two million additional people potentially undiagnosed.
• Insmed plans to engage with authorities across the EU to secure access to BRINSUPRI for eligible patients starting in early 2026.
• Applications for brensocatib are also under review with regulatory agencies in the U.K. and Japan.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the European Commission's approval of BRINSUPRI as the first and only treatment for NCFB in the EU. This represents a significant regulatory and commercial milestone, addressing a large unmet medical need with strong clinical data. While there are noted adverse reactions, the overall impact of being first-in-class in a substantial market is overwhelmingly positive.

Positives

• BRINSUPRI is the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union, addressing a significant unmet medical need.
• The drug is a first-in-class DPP1 inhibitor, offering a novel mechanism of action for a chronic, progressive lung disease.
• Clinical trials (ASPEN and WILLOW) demonstrated strong efficacy, including a 19.4% reduction in annual exacerbation rates with BRINSUPRI 25 mg.
• BRINSUPRI significantly prolonged the time to first exacerbation and increased the proportion of patients remaining exacerbation-free.
• Patients treated with BRINSUPRI 25 mg showed statistically significant less decline in lung function (FEV1) at week 52.
• The European Medicines Agency (EMA) reviewed BRINSUPRI under an accelerated assessment pathway, indicating its major interest for public health.
• The NCFB market in the EU is substantial, with an estimated 600,000 diagnosed patients and potentially two million undiagnosed individuals.

Negatives

• The most frequently reported adverse reactions include headache (9.2%), hyperkeratosis (5.9%), dermatitis (4.2%), rash (4.1%), upper respiratory tract infections (3.9%), and dry skin (3.0%).
• Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, gingival and periodontal adverse reactions, and liver function test elevations compared to placebo.
• In the ASPEN trial, the incidence of skin cancers was higher in BRINSUPRI 25 mg treated patients (1.9%) compared to placebo (1.1%).
• The incidence of alopecia was higher in BRINSUPRI treated patients (1.5% for 10mg, 1.6% for 25mg) compared to placebo (0.4%).
• The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

Risks

• Failure to successfully commercialize BRINSUPRI in the U.S. or European Union or to maintain U.S. or EU approval.
• Failure to obtain, or delays in obtaining, regulatory approvals for BRINSUPRI in the United Kingdom or Japan, or approvals being subject to significant limitations or withdrawal.
• Uncertainties in the degree of market acceptance of BRINSUPRI by physicians, patients, third-party payors, and others in the healthcare community.
• Inaccuracies in estimates of the size of potential markets for BRINSUPRI or in data used to identify physicians.
• Expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates may not be met.
• Inability to obtain adequate reimbursement from government or third-party payors for BRINSUPRI or acceptable prices.
• Development of unexpected safety or efficacy concerns related to BRINSUPRI, including data from further clinical trials not being consistent with ASPEN results, potentially leading to label changes, adverse sales, or market withdrawal.
• Failure to comply with agreements related to brensocatib, including the license agreement with AstraZeneca AB.
• Failure to successfully conduct future clinical trials for brensocatib, including inability to enroll or retain sufficient patients.
• Failure to obtain regulatory approval for potential future brensocatib indications.
• Failure of third parties to manufacture sufficient quantities of brensocatib, conduct clinical trials, or comply with agreements and regulations.

Future Outlook

Insmed plans to engage with authorities across the EU to secure access to BRINSUPRI for eligible patients beginning in early 2026. The company also has applications for brensocatib under review with regulatory bodies in the U.K. and Japan, indicating potential for further market expansion. Management believes BRINSUPRI has the potential to become the new standard of care for treating NCFB patients with prior exacerbations.

Management Comments

• "The European Commission's approval represents a major milestone for patients and clinicians in Europe, offering a much-needed treatment that can help reduce exacerbations, potentially slow disease progression, and reshape the treatment landscape for this debilitating disease." James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK.
• "With BRINSUPRI, we now have the first treatment for non-cystic fibrosis bronchiectasis approved in the European Union—a historically overlooked population with long-standing unmet medical needs." Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.
• "The accelerated approval reflects the strength of the data and the potential to become the new standard of care for treating patients with non-cystic fibrosis bronchiectasis who had at least two prior exacerbations." Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.

Industry Context

The approval of BRINSUPRI marks a significant advancement in the treatment of non-cystic fibrosis bronchiectasis (NCFB), a chronic and progressive lung disease that has historically lacked approved targeted therapies. As the first and only approved treatment for NCFB in the EU, BRINSUPRI addresses a substantial unmet medical need in a patient population estimated to be 600,000 diagnosed individuals, with millions more potentially undiagnosed. This positions Insmed as a leader in this specific therapeutic area, potentially reshaping the treatment landscape and setting a new standard of care.

Comparison to Industry Standards

• BRINSUPRI is the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union, establishing a new benchmark for care in this previously underserved disease area.
• Unlike other respiratory diseases with multiple treatment options, NCFB has lacked specific approved therapies, making BRINSUPRI's approval a unique and pioneering event in the industry.
• The accelerated assessment by the EMA highlights the significant public health interest and the lack of comparable effective treatments available prior to BRINSUPRI.

Stakeholder Impact

• **Shareholders:** Highly positive impact due to significant market expansion and first-in-class drug approval, potentially leading to increased revenue and market valuation.
• **Patients:** Significant positive impact by providing the first approved targeted treatment for NCFB, potentially reducing exacerbations, slowing disease progression, and improving quality of life.
• **Clinicians:** Provides a much-needed therapeutic option for managing NCFB, potentially reshaping treatment paradigms and offering a new standard of care.
• **Regulatory Authorities:** Validation of the drug's safety and efficacy through accelerated assessment, demonstrating a commitment to addressing public health needs.

Next Steps

• Insmed will engage with authorities across the EU to secure access to BRINSUPRI for eligible patients beginning in early 2026.
• Continue with regulatory reviews for brensocatib applications with the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
• Monitor patients for dermatologic adverse reactions and refer to a dermatologist for new findings.
• Refer patients to dental care services for regular dental checkups and advise routine dental hygiene due to gingival and periodontal adverse reactions.
• Avoid the use of live attenuated vaccines in patients receiving BRINSUPRI.

Key Dates

Recommendation

The European Commission's approval of BRINSUPRI as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the EU is a transformative event for Insmed. This represents a significant commercial opportunity in a large, underserved market with strong clinical efficacy data. The first-in-class designation, coupled with ongoing regulatory reviews in other major markets (UK, Japan), positions the company for substantial growth. While there are known side effects, the overall benefit-risk profile and market potential warrant a strong buy recommendation for long-term investors.

Keywords

BRINSUPRI, brensocatib, non-cystic fibrosis bronchiectasis, NCFB, European Commission, EC approval, DPP1 inhibitor, lung disease, biopharmaceutical, Insmed, pulmonary, inflammation